News

Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
The approval of Amgen’s trastuzumab-anns, the fifth biosimilar to Herceptin, marks the twentieth biosimilar approved by the FDA.
Investigators aim to develop cellular models to mimic the biological processes responsible for the onset of multiple sclerosis.
Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.
Top news of the day from across the health care landscape.
Genentech is seeking approval for rituximab (Rituxan) with glucocorticoids for pediatric patients with granulomatosis with polyangiitis and microscopic polyangiitis.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$